Cextuximab, a chimeric human-mouse monoclonal antibody to VEGF receptor is currently under development as an adjuvant agent for colon and rectal cancers.
Cextuximab, a chimeric human-mouse monoclonalantibody to VEGF receptor is currently under developmentas an adjuvant agent for colon and rectal cancers.